Co Diagnostics Stock Today
| CODX Stock | USD 0.89 0.05 5.32% |
Performance0 of 100
| Odds Of DistressLess than 13
|
Co Diagnostics is trading at 0.89 as of the 1st of December 2024; that is 5.32 percent decrease since the beginning of the trading day. The stock's open price was 0.94. Co Diagnostics has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Co Diagnostics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of November 2024 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 12th of July 2017 | Category Healthcare | Classification Health Care |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. The company has 31.93 M outstanding shares of which 229.09 K shares are currently shorted by private and institutional investors with about 2.84 trading days to cover. More on Co Diagnostics
Moving against CODX Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
CODX Stock Highlights
| Chairman | Dwight Egan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCo Diagnostics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Co Diagnostics' financial leverage. It provides some insight into what part of Co Diagnostics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Co Diagnostics (CODX) is traded on NASDAQ Exchange in USA. It is located in 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109 and employs 155 people. Co Diagnostics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.9 M. Co Diagnostics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 31.93 M outstanding shares of which 229.09 K shares are currently shorted by private and institutional investors with about 2.84 trading days to cover.
Co Diagnostics currently holds about 86.49 M in cash with (22.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Co Diagnostics Probability Of Bankruptcy
Ownership AllocationCo Diagnostics secures a total of 31.93 Million outstanding shares. Co Diagnostics owns 6.7 % of its outstanding shares held by insiders and 13.95 % owned by institutions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CODX Ownership Details
CODX Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-09-30 | 55 K | |
| Thompson Davis & Co Inc | 2024-09-30 | 41.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 40.4 K | |
| Uma Financial Services Inc | 2024-06-30 | 31.4 K | |
| Smi Advisory Services Llc | 2024-06-30 | 28 K | |
| Virtu Financial Llc | 2024-06-30 | 27.9 K | |
| Group One Trading, Lp | 2024-06-30 | 26.4 K | |
| Citadel Advisors Llc | 2024-09-30 | 25.4 K | |
| Ubs Group Ag | 2024-06-30 | 22.5 K | |
| Vanguard Group Inc | 2024-09-30 | 1.8 M | |
| Renaissance Technologies Corp | 2024-09-30 | 567.7 K |
Co Diagnostics Historical Income Statement
CODX Stock Against Markets
Co Diagnostics Corporate Management
| Christopher Thurston | Chief Officer | Profile | |
| Andrew Benson | Head Relations | Profile | |
| Mayuranki Almaula | Senior Alliances | Profile | |
| Dan CPA | Vice Accounting | Profile | |
| Ivory Chang | Chief Officer | Profile |
Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.